Sionna Therapeutics Statistics
Share Statistics
Sionna Therapeutics has 44.12M
shares outstanding. The number of shares has increased by null%
in one year.
| Shares Outstanding | 44.12M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | n/a |
| Owned by Institutions (%) | n/a |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | 542 |
| FTD / Avg. Volume | 0.3% |
Short Selling Information
The latest short interest is 2.59M, so 5.87% of the outstanding
shares have been sold short.
| Short Interest | 2.59M |
| Short % of Shares Out | 5.87% |
| Short % of Float | 9.87% |
| Short Ratio (days to cover) | 14.88 |
Valuation Ratios
The PE ratio is -17.2 and the forward
PE ratio is -4.44.
Sionna Therapeutics's PEG ratio is
1.17.
| PE Ratio | -17.2 |
| Forward PE | -4.44 |
| PS Ratio | 0 |
| Forward PS | 9.7 |
| PB Ratio | -6.48 |
| P/FCF Ratio | -20.09 |
| PEG Ratio | 1.17 |
Financial Ratio HistoryEnterprise Valuation
Currently the Enterprise Value (EV) is not available for Sionna Therapeutics.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 14.49,
with a Debt / Equity ratio of -0.06.
| Current Ratio | 14.49 |
| Quick Ratio | 14.49 |
| Debt / Equity | -0.06 |
| Debt / EBITDA | -0.14 |
| Debt / FCF | -0.18 |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | n/a |
| Profits Per Employee | $-1,504,585.37 |
| Employee Count | 41 |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by null% in the
last 52 weeks. The beta is 0, so Sionna Therapeutics's
price volatility has been lower than the market average.
| Beta | 0 |
| 52-Week Price Change | n/a |
| 50-Day Moving Average | 11.96 |
| 200-Day Moving Average | n/a |
| Relative Strength Index (RSI) | 58.23 |
| Average Volume (20 Days) | 181,900 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -70.56M |
| Net Income | -61.69M |
| EBITDA | -69.89M |
| EBIT | -70.56M |
| Earnings Per Share (EPS) | -1.45 |
Full Income StatementBalance Sheet
The company has 37.79M in cash and 9.75M in
debt, giving a net cash position of 28.04M.
| Cash & Cash Equivalents | 37.79M |
| Total Debt | 9.75M |
| Net Cash | 28.04M |
| Retained Earnings | -181.09M |
| Total Assets | n/a |
| Working Capital | n/a |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -52.79M
and capital expenditures -27K, giving a free cash flow of -52.81M.
| Operating Cash Flow | -52.79M |
| Capital Expenditures | -27K |
| Free Cash Flow | -52.81M |
| FCF Per Share | -1.24 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
